01 Company overview
Identity and registration
- Official name
- BRISTOL-MYERS SQUIBB PHARMACEUTICALS LIMITED
- Company number
- 02487574
- Company type
- Private Limited Company
- Status
- Active
- Country of origin
- United Kingdom
- Dissolution date
- Not supplied
A registered office is not necessarily a trading location. The address is reproduced from the Companies House bulk record and should be interpreted in that legal context.
02 Filing dates
Accounts and statements
Last accounts made up to
31 December 2024Next accounts due
30 September 2026Last statement made up to
2 April 2026Next statement due
16 April 2027BritDB does not infer overdue status when the source does not state it.
03 Workforce reporting
Gender pay gap
- Median bonus gap
- 17.2%
- Mean bonus gap
- 15.5%
- Women receiving bonus
- 97.2%
- Men receiving bonus
- 94.0%
- Women in top quartile
- 55.2%
- Women in lower quartile
- 66.7%
Earlier reporting years (7)
- 250 to 4998.6% median hourly gap
- 250 to 49910.9% median hourly gap
- 250 to 4992.5% median hourly gap
- 250 to 4991.1% median hourly gap
- 250 to 4994.5% median hourly gap
- 250 to 4996.0% median hourly gap
- 250 to 4999.2% median hourly gap
Positive gaps mean men were paid more; negative gaps mean women were paid more. These figures are employer-reported and describe the workforce distribution, not equal pay for the same job. The company link uses the exact Companies House number supplied by the service.
04 Supplier payments
Payment practices and performance
- Reporting period
- 1 January 2026 – 30 June 2026
- Filed
- 17 August 2026
- Shortest standard term
- 0 days
- Longest standard term
- 90 days
- E-invoicing offered
- Yes
- Supply-chain finance
- Not offered
- Payment codes
- No
- Construction retentions
- No retention clauses reported
Reported terms and dispute process
- Standard payment terms
The preferred BMS terms for 3rd party vendors are default to 90 days. Payment terms are outlined in contracts with suppliers. Where a contract is not negotiated, the payment terms will be clearly stated on the Purchase Orders (POs) sent to suppliers. Any changes to the payment terms would require a contract amendment.
For Health Care Professionals the standard payment terms are immediate, therefore meeting these terms are difficult to achieve when we consider time to send the invoice, process, approve and release for payment, currently 73% of the above reported late payments are due to Immediate payment terms. Intercompany transactions may also negatively impact the On-time payment percentage due to the Intercompany monthly netting schedule (a further 11% of late payments). - Other payment-term information
NA
- Dispute resolution process
BMS has a dedicated Accounts Payable helpdesk in the event of a dispute with a supplier that offers them support through to query resolution. This query can be raised via email at frontoffice-UK@bms.com. If needed the query is then forwarded to the BMS contact (contract monitor or requisitioner) for further investigation.
Earlier payment reports (11 shown)
- 45.0 average days to pay22.0% outside terms
- 50.0 average days to pay22.0% outside terms
- 42.0 average days to pay27.0% outside terms
- 42.0 average days to pay27.0% outside terms
- 40.0 average days to pay24.0% outside terms
- 40.0 average days to pay27.0% outside terms
- 40.0 average days to pay28.0% outside terms
- 46.0 average days to pay28.0% outside terms
- 41.0 average days to pay31.0% outside terms
- 45.0 average days to pay31.0% outside terms
- 38.0 average days to pay36.0% outside terms
This is a company-submitted statutory disclosure, not a credit rating. BritDB preserves the reporting period and links the report only through the Companies House number supplied by the official service. Percentages describe payments made during that period and may change in later reports.
05 Global legal identity
Legal Entity Identifier
BRISTOL-MYERS SQUIBB PHARMACEUTICALS LIMITED
LEI 5493001TSEVIRTZ8BR07 · jurisdiction GB
- Legal form
- 8888
- Next renewal
- 27 February 2019
- Headquarters address
- SANDERSON ROAD, UXBRIDGE BUSINESS PARK, UXBRIDGE, GB-HIL, UB8 1DH, GB
LEI data provides a global legal-entity identity, not a credit or regulatory approval. BritDB links these records only through GLEIF’s Companies House registration-authority identifier and exact company number.
06 Supply-chain transparency
Modern slavery statement
- Organisation
- BRISTOL-MYERS SQUIBB PHARMACEUTICALS LIMITED
- Group submission
- No
- Statement period
- 1 January 2024 – 31 December 2024
- Approved
- 5 June 2025
- Sectors
- Healthcare and pharmaceuticals
Organisation structure
Covered in the statement
Policies
Covered in the statement
Risk assessment
Covered in the statement
Due diligence
Covered in the statement
Training
Covered in the statement
Goals and KPIs
Covered in the statement
A registry entry records what the organisation declared in its statement. It is not an independent audit. Group statements can cover several companies; BritDB preserves each exact source-supplied company-number link and excludes approver names and email addresses.
07 Data protection
ICO fee-payer registration
Bristol-Myers Squibb Pharmaceuticals Limited
Registration Z7448711
- Registered from
- 15 August 2003
- Current end date
- 14 August 2027
This is a candidate association, not an official Companies House link. The ICO file supplies no company number. The organisation name and postcode uniquely matched this company in the current snapshot. BritDB excludes all DPO contact fields and does not publish unmatched personal entries.
08 Public procurement
Contracts Finder awards
NHS Framework, North of England, Branded Medicines-Tranche A and Annual Tranche
NHS England · ocds-b5fd17-711f74f7-430c-4b80-a5e0-b3ce69f928b9
- Award value
- £1
- Contract period
- 1 March 2021 – 28 February 2023
- Procedure
- Open procedure (above threshold)
NHS Framework for the Midlands and East, Branded Medicines - Tranche B
NHS England · ocds-b5fd17-a3813112-7a5b-461b-9e42-ccdb117c93ef
- Award value
- £228,156,862
- Contract period
- 1 March 2021 – 28 February 2023
- Procedure
- Open procedure (above threshold)
NHS Framework for the NHS London Region, Branded Medicines - Tranche A
NHS England · ocds-b5fd17-20ae12c6-3ba8-40bb-b423-51a2c2de6a67
- Award value
- £191,062,951
- Contract period
- 1 September 2020 – 31 August 2022
- Procedure
- Open procedure (above threshold)
NHS Framework Agreement - North of England - Tranche B
NHS England · ocds-b5fd17-2774d91d-05e7-400d-a217-4a5ca9db01ef
- Award value
- £205,535,556
- Contract period
- 1 March 2020 – 28 February 2022
- Procedure
- Open procedure (above threshold)
NHS Midlands and East Branded Medicines - Tranche A
NHS England · ocds-b5fd17-1d021051-40c8-4883-ba04-47625826b7b8
- Award value
- £418,787,000
- Contract period
- 1 March 2020 – 28 February 2022
- Procedure
- Open procedure (above threshold)
NHS South of England Branded Medicines - Tranche A - Contracts Finder Award Notice
NHS England · ocds-b5fd17-8b5e045d-6a03-4c26-b452-fcd5b23d5349
- Award value
- £188,004,961
- Contract period
- 1 September 2019 – 31 August 2021
- Procedure
- Open procedure (above threshold)
NHS Framework Agreement for Branded medicines - London - Tranche B - Contracts Finder Opportunity
NHS England · ocds-b5fd17-aaa2bd9e-0fdb-4884-8fca-b0d29a6ed15a
- Award value
- £251,930,337
- Contract period
- 1 September 2019 – 31 August 2020
- Procedure
- Open procedure (above threshold)
NHS Framework Agreement for Branded Medicines - National
NHS England · ocds-b5fd17-67d93048-4af9-4a0e-b313-bc852f01fca7
- Award value
- £1,351,341,890
- Contract period
- 1 May 2019 – 30 April 2021
- Procedure
- Open procedure (above threshold)
NHS England - Midlands and East Branded Medicines - Tranche B
NHS England · ocds-b5fd17-6c7a4e2c-58d3-4c41-8f77-dc419f83871c
- Award value
- £295,035,882
- Contract period
- 1 March 2019 – 28 March 2021
- Procedure
- Open procedure (above threshold)
NHS England - Midlands and East Branded Medicines - Tranche B
NHS England · ocds-b5fd17-9878d09a-d11a-4940-a851-2b2b759217f2
- Award value
- £295,035,882
- Contract period
- 1 March 2019 – 28 March 2021
- Procedure
- Open procedure (above threshold)
NHS England - Midlands and East Branded Medicines - Tranche B
NHS England · ocds-b5fd17-679e36df-b147-44d9-b0c1-53e4b91250c8
- Award value
- £295,035,882
- Contract period
- 1 March 2019 – 28 March 2021
- Procedure
- Open procedure (above threshold)
NHS England - Midlands and East Branded Medicines - Tranche B
NHS England · ocds-b5fd17-8aaddf75-dd22-4754-b241-885b44819814
- Award value
- £295,035,882
- Contract period
- 1 March 2019 – 28 March 2021
- Procedure
- Open procedure (above threshold)
NHS England Framework Agreement: South of England (Tranche B)
NHS England · ocds-b5fd17-3dac71e6-cde5-406b-abc4-e91389859bf5
- Award value
- £501,400,000
- Contract period
- 1 September 2018 – 31 August 2020
- Procedure
- Open procedure (above threshold)
NHS England Framework Agreement - London - Tranche A
NHS England · ocds-b5fd17-7b2dd479-3a52-442f-a080-4372505d9351
- Award value
- £211,435,404
- Contract period
- 1 September 2018 – 31 August 2020
- Procedure
- Open procedure (above threshold)
The supplier link is exact, but the award remains buyer-published procurement data. BritDB requires the GB-COH identifier supplied in the Contracts Finder OCDS release and does not infer suppliers from similar names.
TM UK trade marks
Exact owner-name matches
SQUIBB
Owner Bristol-Myers Squibb Pharmaceuticals Limited · classes 16
- Filed / designated
- 16 March 1987
- Valid until / renewal due
- 16 March 2018
REMIDERM-N
Owner Bristol-Myers Squibb Pharmaceuticals Limited · classes 5
- Filed / designated
- 21 September 1984
- Valid until / renewal due
- 21 September 2025
HALCORT-FORTE
Owner Bristol-Myers Squibb Pharmaceuticals Limited · classes 5
- Filed / designated
- 7 March 1978
- Valid until / renewal due
- 7 March 2019
SQUIBB
Owner Bristol-Myers Squibb Pharmaceuticals Limited · classes 5
- Filed / designated
- 22 February 1978
- Valid until / renewal due
- 22 February 2019
SQUIBB
Owner Bristol-Myers Squibb Pharmaceuticals Limited · classes 10
- Filed / designated
- 2 February 1977
- Valid until / renewal due
- 2 February 2018
SQUIBB
Owner Bristol-Myers Squibb Pharmaceuticals Limited · classes 1
- Filed / designated
- 12 February 1974
- Valid until / renewal due
- 12 February 2025
HALCIDERM
Owner Bristol-Myers Squibb Pharmaceuticals Limited · classes 5
- Filed / designated
- 6 June 1973
- Valid until / renewal due
- 6 June 2018
NYSTADERMAL
Owner Bristol-Myers Squibb Pharmaceuticals Limited · classes 5
- Filed / designated
- 21 March 1973
- Valid until / renewal due
- 21 March 2018
MYCOSTATIN
Owner Bristol-Myers Squibb Pharmaceuticals Limited · classes 5
- Filed / designated
- 17 November 1971
- Valid until / renewal due
- 17 November 2026
VELOSEF
Owner Bristol-Myers Squibb Pharmaceuticals Limited · classes 5
- Filed / designated
- 27 September 1971
- Valid until / renewal due
- 27 September 2026
BIADCORTYL
Owner Bristol-Myers Squibb Pharmaceuticals Limited · classes 5
- Filed / designated
- 23 December 1970
- Valid until / renewal due
- 23 December 2025
ANATENSOL
Owner Bristol-Myers Squibb Pharmaceuticals Limited · classes 5
- Filed / designated
- 21 December 1970
- Valid until / renewal due
- 21 December 2025
MODECATE
Owner Bristol-Myers Squibb Pharmaceuticals Limited · classes 5
- Filed / designated
- 19 January 1968
- Valid until / renewal due
- 19 January 2023
PLASTIBASE
Owner Bristol-Myers Squibb Pharmaceuticals Limited · classes 5
- Filed / designated
- 29 March 1966
- Valid until / renewal due
- 29 March 2021
FUNGILIN
Owner Bristol-Myers Squibb Pharmaceuticals Limited · classes 5
- Filed / designated
- 6 December 1965
- Valid until / renewal due
- 6 December 2020
NYSTAN
Owner Bristol-Myers Squibb Pharmaceuticals Limited · classes 5
- Filed / designated
- 11 November 1965
- Valid until / renewal due
- 11 November 2020
HYDREA
Owner Bristol-Myers Squibb Pharmaceuticals Limited · classes 5
- Filed / designated
- 6 July 1965
- Valid until / renewal due
- 6 July 2020
SQUIBB
Owner Bristol-Myers Squibb Pharmaceuticals Limited · classes 3
- Filed / designated
- 13 November 1964
- Valid until / renewal due
- 13 November 2019
SQUIBB
Owner Bristol-Myers Squibb Pharmaceuticals Limited · classes 21
- Filed / designated
- 13 November 1964
- Valid until / renewal due
- 13 November 2019
SQUIBB
Owner Bristol-Myers Squibb Pharmaceuticals Limited · classes 5
- Filed / designated
- 25 August 1964
- Valid until / renewal due
- 25 August 2019
ADCORTYL
Owner Bristol-Myers Squibb Pharmaceuticals Limited · classes 5
- Filed / designated
- 22 May 1964
- Valid until / renewal due
- 22 May 2019
PLASTIBASE
Owner Bristol-Myers Squibb Pharmaceuticals Limited · classes 1
- Filed / designated
- 26 March 1964
- Valid until / renewal due
- 26 March 2019
KENACOMB
Owner Bristol-Myers Squibb Pharmaceuticals Limited · classes 5
- Filed / designated
- 6 March 1964
- Valid until / renewal due
- 6 March 2019
TRI-ADCORTYL
Owner Bristol-Myers Squibb Pharmaceuticals Limited · classes 5
- Filed / designated
- 17 October 1960
- Valid until / renewal due
- 17 October 2025
MODITEN
Owner Bristol-Myers Squibb Pharmaceuticals Limited · classes 5
- Filed / designated
- 17 February 1960
- Valid until / renewal due
- 17 February 2025
RAUTRAX
Owner Bristol-Myers Squibb Pharmaceuticals Limited · classes 5
- Filed / designated
- 26 March 1959
- Valid until / renewal due
- 26 March 2018
KENALOG
Owner Bristol-Myers Squibb Pharmaceuticals Limited · classes 5
- Filed / designated
- 30 December 1958
- Valid until / renewal due
- 30 December 2027
ADCORTYL
Owner Bristol-Myers Squibb Pharmaceuticals Limited · classes 5
- Filed / designated
- 22 January 1958
- Valid until / renewal due
- 22 January 2027
SQUIBB
Owner Bristol-Myers Squibb Pharmaceuticals Limited · classes 5
- Filed / designated
- 24 February 1956
- Valid until / renewal due
- 24 February 2025
FUNGIZONE
Owner Bristol-Myers Squibb Pharmaceuticals Limited · classes 5
- Filed / designated
- 13 July 1954
- Valid until / renewal due
- 13 July 2023
This is an exact normalised company-name match, not a registrar-confirmed ownership link. Another legal entity can have the same or a very similar name. UKIPO data is a historical 2018 snapshot; verify the owner and current status before relying on it.
09 Ownership and control
People with significant control
Bristol-Myers Squibb Holdings 2002 Limited
- Owns 75% or more of shares
- Controls 75% or more of voting rights
- Can appoint or remove directors
- Notified
- 6 April 2016
PSC records are company-filed public-register information. When the exact same displayed individual name occurs at multiple companies, BritDB offers a non-indexed cross-reference page. It is a name match only, not proof that the records describe the same person. Service addresses and partial dates of birth are deliberately omitted.
10 Charity register
Charity Commission links
No exact company-number link in this snapshot
The Charity Commission extract did not explicitly associate this Companies House number with a charity. BritDB does not use a name-only match to fill the gap.
This company-level check covers the Charity Commission for England and Wales. Links are accepted only when the official extract supplies this exact company registration number. Scottish charities now have separate OSCR profiles, but OSCR’s bulk fields do not provide a Companies House number, so BritDB does not infer a company link.
11 Northern Ireland charity register
CCNI exact company links
No unambiguous company-number link found
The CCNI source number did not resolve uniquely to this Companies House record. BritDB did not use a name or address match.
CCNI publishes company numbers without a jurisdiction prefix. BritDB links only when the plausible padded UK and NI candidates resolve to exactly one Companies House company.
12 Sanctions screening
UK Sanctions List
No exact business-registration-number link found
The imported UK Sanctions List did not supply this Companies House number as a UK-linked business identifier. BritDB did not attempt a name-only match.
No exact link is not sanctions clearance. UK restrictions can apply through ownership or control even where an entity is not separately named. Always use the current official list and obtain appropriate advice for a legally significant decision.
13 Public procurement
Find a Tender links
Provision of Breyanzi CAR POS T-Cells
The Clatterbridge Cancer Centre NHS Foundation Trust · updated 17 August 2026
- Tender value
- Not supplied
- Awards
- 2
OPDIVO (NIVOLUMAB) 600MG/5ML SOLUTION FOR INJECTION VIAL, 5 mL
Belfast Health & Social Care Trust · updated 7 July 2026
- Tender value
- Not supplied
- Awards
- 1
YERVOY (IPILIMUMAB) CONCENTRATE FOR SOLUTION FOR INFUSION vial, PACK OF 1
Belfast Health & Social Care Trust · updated 7 July 2026
- Tender value
- Not supplied
- Awards
- 1
Provision of Breyanzi CAR POS T-Cells
The Clatterbridge Cancer Centre NHS Foundation Trust · updated 29 June 2026
- Tender value
- Not supplied
- Awards
- 2
Provision of Breyanzi CAR POS T-Cells
The Clatterbridge Cancer Centre NHS Foundation Trust · updated 11 May 2026
- Tender value
- Not supplied
- Awards
- 2
Provision of Breyanzi CAR POS T Cells
The Clatterbridge Cancer Centre NHS Foundation Trust · updated 6 March 2026
- Tender value
- Not supplied
- Awards
- 2
BH_NonClinical_Pharmacy_Car-T
Barts Health NHS Trust · updated 26 November 2025
- Tender value
- Not supplied
- Awards
- 1
NIVOLUMAB 240MG/RELATLIMAB 80MG (OPDUALAG ) Solution for Infusion 1 Vial Pack
BELFAST HEALTH AND SOCIAL CARE TRUST · updated 10 February 2025
- Tender value
- Not supplied
- Awards
- 1
POMALIDOMIDE 4 mg Capsules 21 Capsule Pack
BELFAST HEALTH AND SOCIAL CARE TRUST · updated 19 November 2024
- Tender value
- Not supplied
- Awards
- 1
Contract for POMALIDOMIDE (Imnovid) Capsules
Northern Health and Social Care Trust · updated 28 October 2024
- Tender value
- Not supplied
- Awards
- 1
Bristol Myers Squibb - WT2024-28 - POMALIDOMIDE (1mg, 2 mg, 3mg, 4mg) Capsules
Western Health and Social Care Trust · updated 10 October 2024
- Tender value
- Not supplied
- Awards
- 1
NIVOLUMAB 240MG/RELATLIMAB 80MG (OPDUALAG ) Solution for Infusion 1 Vial Pack
BELFAST HEALTH AND SOCIAL CARE TRUST · updated 21 August 2024
- Tender value
- Not supplied
- Awards
- 1
Contract for POMALIDOMIDE (Imnovid) Capsules
Northern Health and Social Care Trust · updated 30 January 2024
- Tender value
- Not supplied
- Awards
- 1
Contract for POMALIDOMIDE (Imnovid) Capsules
Northern Health and Social Care Trust · updated 30 August 2023
- Tender value
- Not supplied
- Awards
- 1
These links use only the GB-COH identifier supplied in the procurement record. A company may have other public-sector work that is absent, older, below publication thresholds or published without a Companies House identifier.
14 Environmental register
Environment Agency waste registrations
No exact company-number registration linked
The licensed Environment Agency subset did not contain this exact Companies House number. BritDB did not attempt a name-only match.
This is a privacy-reduced, exact-company subset. The full official register also includes sole traders and applicants without a matching Companies House number. Check the current Environment Agency register before relying on registration status.
15 Nature of business
Standard Industrial Classification
Manufacture of basic pharmaceutical products
16 Connected public record
Checks beyond the company register
Charity Commission
0 exact company-number links.
Northern Ireland charities
0 unambiguous company-number links.
Public contracts
14 procurement processes linked by exact GB-COH identifier.
Waste register
0 exact company-number registrations.
Corporate notices
The Gazette is not yet connected.
UK Sanctions List
No exact business-registration-number link in this report.
A checked source with no exact link is not a clean bill of health. Unchecked sources remain unknown, while sanctions may also apply through ownership or control of a listed person or entity.
17 Record timeline
Dates in the bulk record
- Confirmation statement
Latest confirmation statement made up to this date
- Accounts
Latest accounts made up to this date
- Incorporation
Company incorporated
18 Provenance
Sources for this profile
Identity, address, status, dates, SIC, previous names and mortgage totals.
Annual employer reports linked by the exact source-supplied Companies House number.
Statutory supplier-payment reports linked by the exact source-supplied Companies House number.
Global legal identities linked through Companies House registration authority RA000585.
Annual statement summaries linked by exact source company number.
Privacy-reduced candidate associations based on a unique exact name-and-postcode match.
Historic awards linked by exact source-supplied GB-COH company identifier.
Current and ceased significant-control records joined by exact company number.
Daily England and Wales extract matched only by the official company registration number.
Daily CCNI export with company links only where the source number resolves unambiguously.
Complete FCDO list checked by exact UK-linked business registration number.
Procurement parties checked only through exact GB-COH identifiers.
Licensed subset linked only by exact Companies House number.
Financial regulation and licences.
Companies House, Charity Commission, OSCR and UK Sanctions List information is public-register data. BritDB reproduces and organises it with source-specific limits; official external links are kept on the dedicated source pages.